Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

 Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Shots:

  • The FIREFISH study involves assessing of Risdiplam in infants aged 1-7 mos. with Type 1 SMA
  • The P-II FIREFISH study results: met its 1EPs i.e, the proportion of infants sitting without support for at least 5sec @12mos. of treatment, assessed by the Gross Motor Scale of BSID-III, consistent safety profile with no new safety signals
  • Risdiplam is an investigational SMN2 splicing modifier for SMA, currently being evaluated in 4 multicenter studies and has received US FDA’s PR status with its expected approval by 24 May, 2019

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post